In hepatitis B drug market, 'Viread (Tenofovir)' is showing an upward tendency
In hepatitis B drug market, 'Viread (Tenofovir)' is showing an upward tendency.
Its prescription cost exceeded already 10 billion won this year, and is increasing market share.
According to data from Ubist, it turned out that outpatient prescription of hepatitis B drug 'Viread' in Feb was 5.2 b...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
